BRIEF-MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)

May 21 (Reuters) - Maat Pharma SA MAAT.PA:

  • MAAT PHARMA PROVIDES AN UPDATE ON THE APPLICATION FOR MARKETING AUTHORIZATION OF MAAT013 (XERVYTEG®) IN THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE

  • MAAT PHARMA SA - RECEIVES 'NEGATIVE TREND' OPINION FOR UPCOMING JUNE CHMP VOTE

  • MAAT PHARMA SA - TO REQUEST RE-EXAMINATION OF MAAT013 APPLICATION AFTER JUNE CHMP VOTE

  • MAAT PHARMA SA - EXTENDS FINANCIAL VISIBILITY INTO NOVEMBER 2026

Source text: ID:nBw9x1mfBa

Further company coverage: MAAT.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.